SLC5A2 and hydrops fetalis: Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), is recommended for all patients with Heart failure (HF) who have been treated with ACE-I/ARNI, β-blockers, and MRA, regardless of diabetes, to reduce the risk of Cardiovascular (CV) death, hospitalization, and HF exacerbation in HF patients (1–4).